Comparative Pharmacology
Head-to-head clinical analysis: ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE versus METHYCLOTHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE versus METHYCLOTHIAZIDE.
ENALAPRIL MALEATE AND HYDROCHLOROTHIAZIDE vs METHYCLOTHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Enalapril is an angiotensin-converting enzyme (ACE) inhibitor that inhibits the conversion of angiotensin I to angiotensin II, reducing vasoconstriction and aldosterone secretion, leading to decreased blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing sodium, chloride, and water excretion, and reducing peripheral vascular resistance.
Thiazide-like diuretic that inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water. Reduces peripheral vascular resistance.
Oral: Initially enalapril 5 mg and HCTZ 12.5 mg once daily; titrate to maximum enalapril 20 mg / HCTZ 25 mg once daily.
2.5-10 mg orally once daily.
None Documented
None Documented
Clinical Note
moderateMethyclothiazide + Digoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digoxin."
Clinical Note
moderateMethyclothiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Digitoxin."
Clinical Note
moderateMethyclothiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Deslanoside."
Clinical Note
moderateEnalaprilat: terminal 11 hours (multiple doses), prolonged in renal impairment (creatinine clearance <30 mL/min: 30-40 h). Hydrochlorothiazide: terminal 6-15 hours (mean 10 h), prolonged in renal impairment.
Terminal elimination half-life: ~40 hours (range 30-50 h); due to extensive tubular reabsorption, half-life is prolonged in renal impairment and elderly, allowing once-daily dosing
Enalapril: renal 60-80% (40-60% as enalaprilat, 20-40% as metabolites); fecal 20-40%. Hydrochlorothiazide: renal 95% (unchanged).
Primarily renal (70-80% as unchanged drug via tubular secretion and glomerular filtration); minor biliary/fecal (<10%)
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic
Methyclothiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Acetyldigitoxin."